Skip to content

A Trial to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer

Randomized Controlled Trial to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer(JCOG 0404,CRC Surg-LAP/OPEN)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00147134
Enrollment
1050
Registered
2005-09-07
Start date
2004-11-30
Completion date
2014-03-31
Last updated
2016-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

colorectal cancer, laparoscopic surgery, randomized controlled trial, oncological outcome

Brief summary

The purpose of this study is to evaluate oncological outcome of patients for T3 and T4 colorectal cancer undergoing laparoscopic versus open surgery.

Detailed description

The benefits of laparoscopic surgery (LAP) in comparison to open surgery (OPEN) have been suggested with respect to decreased morbidity, decreased pain, faster recovery, and shorter hospital stay.1-4 However, the long-term survival of LAP for colorectal cancer is still unclear, especially for advanced colorectal cancer requiring extended lymphadenectomy. Thus, the investigators designed a study which investigates whether LAP is suitable for advanced colorectal cancer with respect to survival and post-operative morbidity.

Interventions

Procedure/Surgery: open colectomy

Procedure/Surgery: laparoscopic colectomy

Sponsors

Ministry of Health, Labour and Welfare, Japan
CollaboratorOTHER_GOV
Haruhiko Fukuda
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Histologically proven colorectal carcinoma 2. Tumor located in the cecum, ascending colon, sigmoid colon, or rectosigmoid colon 3. T3 or deeper lesion without involvement of other organs 4. Without multiple lesion other than carcinoma in situ 5. Cancer classified as N0-2 and M0, according to the TNM classification system 6. Tumor size \< 8 cm 7. No bowel obstruction 8. Age 20 \< and \> 75 years 9. Sufficient organ function 10. No history of gastrointestinal surgery 11. No history of chemotherapy or radiotherapy 12. Provided written informed consent

Exclusion criteria

1. Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ 2. Severe pulmonary emphysema, interstitial pneumonitis, or ischemic heart disease 3. Pregnant or lactating women 4. Severe mental disease 5. Continuous systemic steroid therapy

Design outcomes

Primary

MeasureTime frame
Overall survivalDuring the study conduct

Secondary

MeasureTime frame
Relapse-free survivalDuring the study conduct
Short-term clinical outcomestime to 1st discharge after operation
Adverse eventsDuring the study conduct
The proportion of conversion from LAP to OPENoperation day
The proportion of completion of LAPoperation day

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026